fmc full year year-six earnings are now expected to be in the range of $num-one to $num-two per diluted share, a year-over-year increase of num-three% at the midpoint.
adjusted earnings were $num-one per diluted share in the quarter, an increase of num-two% versus qtr-two year-five and also $num-three above the midpoint of our guidance range.
our second quarter results, revenue up num-one%, ebitda up num-two% and earnings per share up num-three% year-over-year were slightly ahead of our guidance.
ebitda is now expected to be in the range of $num-one billion to $num-two billion, representing a num-three% year-over-year growth at the midpoint.
our year-six revenue forecast remains in the range of $num-one billion to $num-two billion, an increase of num-three% at the midpoint versus year-five.
we reported $num-one billion in second quarter revenue, which reflects an num-two% increase on a reported basis and a num-three% increase organically.
ebitda margins were num-one%, a decrease of num-two basis points compared to the prior year, reflecting the impact of continued and accelerating cost headwinds.
we are forecasting ebitda growth of num-one% at the midpoint versus qtr-four year-five, and earnings per share is forecasted to be up num-two% year-over-year.
new products introduced in the last num-one months contributed $num-two million in sales growth in the quarter and our plant health products, including biologicals, posted qtr-two sales growth in the high teens.
adjusted ebitda was $num-one million, an increase of num-two% compared to the prior year period and $num-two million above the midpoint of our guidance range.
for the full year, we continue to anticipate paying dividends of roughly $num-one million, and now expect to repurchase a total of $num-two million to $num-three million of fmc shares this year, with the outlook for repurchases down slightly, reflecting the lower ebitda guidance.
we are forecasting ebitda growth of num-one% at the midpoint versus qtr-three year-five, and earnings per share is forecasted to be up num-two% year-over-year.
our effective tax rate on adjusted earnings for the second quarter was num-one% as anticipated and in line with our continued expectation for the full year tax rate.
guidance for qtr-four implies year-over-year sales growth of num-one% at the midpoint on a reported basis with no fx impact anticipated.
guidance for qtr-three implies year-over-year sales growth of num-one% at the midpoint on a reported basis and num-two% organically.
with the reduction in our outlook for full year ebitda, we are similarly adjusting downward our expectations for free cash flow to a range of $num-one million to $num-two million, with the vast majority of this cash flow coming in the fourth quarter.